09:36 AM EST - Tekmira Pharmaceuticals Corp. : said it has initiated a Phase 1 human clinical trial for ApoB SNALP. ApoB SNALP, Tekmira's lead RNAi therapeutic product candidate, is being developed as a treatment for patients with elevated low-density lipoprotein, or LDL, cholesterol, or "bad" cholesterol, who are not well served by current therapy. The company specified that the Phase 1 clinical trial will evaluate the safety, tolerability and pharmacokinetics of escalating single doses of ApoB SNALP in approximately 30 patients with elevated LDL cholesterol. Each dosing cohort will include four patients; three patients will receive ApoB SNALP and one patient will receive a placebo. The trial is also designed to provide preliminary data on the ability of ApoB SNALP to lower serum LDL cholesterol levels. Tekmira Pharmaceuticals Corp.
shares T.TKM are trading even at $1.15.
